Twist Bioscience (TWST) Projected to Post Earnings on Monday

Twist Bioscience (NASDAQ:TWST) is anticipated to announce its Q1 2026 results before the market opens on Monday, February 2nd. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $100.3160 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, February 2, 2026 at 8:00 AM ET.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The business had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Stock Down 4.9%

Shares of TWST stock opened at $42.94 on Monday. The stock’s fifty day moving average price is $33.70 and its 200 day moving average price is $31.41. Twist Bioscience has a 1-year low of $23.30 and a 1-year high of $55.33. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -32.78 and a beta of 2.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33.

Insiders Place Their Bets

In other news, CAO Robert F. Werner sold 1,016 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $31,943.04. Following the sale, the chief accounting officer owned 51,030 shares of the company’s stock, valued at $1,604,383.20. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Emily M. Leproust sold 1,605 shares of Twist Bioscience stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $34.56, for a total transaction of $55,468.80. Following the transaction, the chief executive officer directly owned 874,313 shares of the company’s stock, valued at approximately $30,216,257.28. This trade represents a 0.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 66,437 shares of company stock worth $2,136,365. Corporate insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC grew its holdings in Twist Bioscience by 151.5% in the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock valued at $50,479,000 after purchasing an additional 1,080,722 shares during the period. Balyasny Asset Management L.P. grew its stake in Twist Bioscience by 934.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 628,241 shares of the company’s stock valued at $23,113,000 after acquiring an additional 567,481 shares during the period. Bank of America Corp DE grew its stake in Twist Bioscience by 143.4% in the 2nd quarter. Bank of America Corp DE now owns 688,332 shares of the company’s stock valued at $25,324,000 after acquiring an additional 405,560 shares during the period. Soleus Capital Management L.P. purchased a new stake in Twist Bioscience in the 2nd quarter worth $13,038,000. Finally, UBS Group AG raised its position in Twist Bioscience by 137.7% during the third quarter. UBS Group AG now owns 514,928 shares of the company’s stock worth $14,490,000 after acquiring an additional 298,331 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on TWST shares. Barclays boosted their price target on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Evercore ISI reiterated an “outperform” rating and issued a $42.00 target price on shares of Twist Bioscience in a research note on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Stephens began coverage on Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus target price of $44.67.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.